Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab plus CTD versus CTD for relapsed/refractory multiple myeloma
ACTRN12616001030460Phase 3Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of elotuzumab, cyclophosphamide, thalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started Jan 2017; status: active, not recruiting.
02
Drugs
elotuzumabcyclophosphamidethalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12616001030460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001030460.